Patient	Risk	Diagnosis	Mutation 1	Mutation 2	Treatment	Treatment_Type	Samples available	known progression	rnaediting
727	AP CML	AP CML	BCR-ABL			no treatment or hydroxyurea	PB+S		yes
743	CLL	CLL	CLL			no treatment or hydroxyurea	PB+S		
607	CML	CML	BCR-ABL			no treatment or hydroxyurea	PB+S		
726	CP CML	CP CML	BCR-ABL	CALR+		no treatment or hydroxyurea	PB+S	post-ET	
725	Essential Thrombocythemia	ET	V617F+	CALR+		no treatment or hydroxyurea	PB+S	post-PV	yes
289	Essential Thrombocythemia	ET	V617F+			no treatment or hydroxyurea	PB+S		
641	Essential Thrombocythemia	ET	V617F+			no treatment or hydroxyurea	PB+S	post-ET	
731	Essential Thrombocythemia	ET	V617F-			no treatment or hydroxyurea	PB+S		
576	High Risk Myelofibrosis	MF	V617F+	CALR-	pacritinib	Jak2 Inhibitor	PB+S	post-PV	yes
580	Intermediate Risk Myelofibrosis	MF	V617F+		Jakafi	Jak2 Inhibitor	PB+S		yes
600	High Risk Myelofibrosis	MF	V617F+		Jakafi	Jak2 Inhibitor	PB+S	post-ET	yes
668	Intermediate Risk Myelofibrosis	MF	V617F+	CALR-	Jakafi	Jak2 Inhibitor	PB+S		yes
721	Intermediate Risk Myelofibrosis	MF	V617F+	CALR-	Jakafi	Jak2 Inhibitor	PB+S		yes
744	High Risk Myelofibrosis	MF	V617F+		Jakafi	Jak2 Inhibitor	PB+S	post-PV	yes
767	Intermediate Risk Myelofibrosis	MF	V617F+		hydroxyurea	no treatment or hydroxyurea	PB+S		yes
623	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
627	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
670	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S	post-PV	
705	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
729	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
739	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
742	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
747	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
749	High Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S	post-ET	
753	Intermediate Risk Myelofibrosis	MF	V617F+	CALR-		no treatment or hydroxyurea	PB+S		
758	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
765	Intermediate Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S	post-PV	
567	High Risk Myelofibrosis	MF	V617F-		pacritinib	Jak2 Inhibitor	PB+S	post-PV	yes
662	Intermediate Risk Myelofibrosis	MF	V617F-	CALR+		no treatment or hydroxyurea	PB+S		yes
664	Intermediate Risk Myelofibrosis	MF	V617F-	CALR-	hydroxyurea	no treatment or hydroxyurea		post-ET	yes
690	Myelofibrosis	MF	V617F-			no treatment or hydroxyurea	PB+S		yes
574	Intermediate Risk Myelofibrosis	MF	V617F-			no treatment or hydroxyurea	PB+S		
624	High Risk Myelofibrosis	MF	V617F-			no treatment or hydroxyurea	PB+S		
707	Intermediate Risk Myelofibrosis	MF	V617F-			no treatment or hydroxyurea	PB 		
733	Intermediate Risk Myelofibrosis	MF	V617F-			no treatment or hydroxyurea	PB+S		
734	High Risk Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
787	Myelofibrosis	MF	V617F+			no treatment or hydroxyurea	PB+S		
780	Normal Control	Normal	Normal			no treatment or hydroxyurea	PB+S	post-PV	
792	Normal Control	Normal	Normal			no treatment or hydroxyurea	PB+S	post-ET	
795	Normal Control	Normal	Normal			no treatment or hydroxyurea	PB+S		
542	Polycythemia Vera	PV	V617F+			no treatment or hydroxyurea	PB		
584	Polycythemia Vera	PV	V617F+			no treatment or hydroxyurea	PB+S		
636	Polycythemia Vera	PV	V617F+			no treatment or hydroxyurea	PB+S		
728	Polycythemia Vera	PV	V617F+			no treatment or hydroxyurea	PB+S		
775	Polycythemia Vera	PV	V617F+			no treatment or hydroxyurea	PB+S		
751	Polycythemia Vera	PV	V617F-			no treatment or hydroxyurea	PB+S		